Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

Heart Failure Drugs: Inotropic Agents

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...

Cardiomyopathy II: Dilated Cardiomyopathy

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

Drug Toxicity: Risk factors

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Therapeutic adherence and health literacy: a perfect match in dyslipidemic patients.

Minerva medica·2026

Same author

Lipid lowering therapy in Tangier disease: what is the best association?

Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis·2026

Same author

Sex-Related Outcome After Sutureless Aortic Valve Replacement With Perceval Plus: Results From a Global Registry and Meta-Regression.

Interdisciplinary cardiovascular and thoracic surgery·2026

Same author

Mitral Valve Endocarditis by Micrococcus luteus: First European Case.

JACC. Case reports·2026

Same author

Lipoprotein apheresis as rescue therapy in lipoprotein glomerulopathy: The role of plasmatic extracellular vesicle removal.

Journal of clinical lipidology·2026

Same author

Lipoprotein apheresis in the era of new lipid-lowering therapies.

European heart journal·2026

Search research articles

Related Experiment Video

Updated: Jun 17, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

[Cardiotoxicity induced by chemo- and radiotherapy].

Vera Srebot¹, Francesco Sbrana, Alessio Maffei

¹Istituto di Fisiologia Clinica e Fondazione Toscana Gabriele Monasterio, Pisa.

Recenti Progressi in Medicina

|January 14, 2010

Summary

Chemotherapy and radiotherapy for Hodgkin lymphoma can lead to early cardiovascular disease, including coronary atherosclerosis and valvular/pericardial issues. This case highlights the long-term cardiac risks associated with cancer treatments.

More Related Videos

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

Related Experiment Videos

Last Updated: Jun 17, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

Area of Science:

Cardiology
Oncology
Cardiovascular Medicine

Background:

Cardiovascular disease (CVD) is a significant concern in cancer survivors.
Cancer therapies like chemotherapy and radiotherapy can induce cardiotoxicity.
Hodgkin lymphoma survivors are at increased risk for long-term health complications.

Observation:

A 55-year-old patient with dyslipidemia and a history of stage 2b Hodgkin lymphoma treated with chemotherapy and radiotherapy presented with cardiovascular issues.
The patient exhibited early coronary atherosclerosis.
Progressive disease included aortic and mitral valve disease and constrictive pericarditis.

Findings:

The patient's cardiovascular complications developed relatively early after cancer treatment.
The observed conditions suggest a link between prior cancer therapy and subsequent cardiac pathology.
Dyslipidemia was the sole traditional cardiovascular risk factor, underscoring the potential impact of cancer treatment.

Implications:

Cancer therapies, including chemotherapy and radiotherapy, may play a direct role in the pathogenesis of cardiovascular disease.
Valvular and pericardial diseases are significant potential long-term adverse effects of Hodgkin lymphoma treatment.
Further research is warranted to understand and mitigate the cardiovascular risks in cancer survivors.